Detalles de la búsqueda
1.
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
Gynecol Oncol
; 185: 128-137, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38412736
2.
A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC).
Int J Gynecol Cancer
; 2024 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38760075
3.
Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both.
Oncologist
; 28(10): e977-e980, 2023 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37665777
4.
Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial.
Gynecol Oncol
; 175: 1-7, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37262961
5.
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
Gynecol Oncol
; 178: 119-129, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37862791
6.
Evaluating open access publication and research impact in gynecologic oncology.
Int J Gynecol Cancer
; 33(7): 1112-1117, 2023 07 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37220951
7.
Best original research presented at the 23rd European Congress on Gynaecological Oncology-Best of ESGO 2022.
Int J Gynecol Cancer
; 33(2): 175-182, 2023 Feb 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36521934
8.
An easy, fast, and accurate way for implementing the standards of care for the management of patients with endometrial carcinoma into daily clinical practice: the ESGO mobile app.
Int J Gynecol Cancer
; 33(8): 1181-1184, 2023 08 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37460218
9.
CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer.
Int J Gynecol Cancer
; 33(8): 1247-1252, 2023 08 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37068851
10.
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
Int J Gynecol Cancer
; 33(8): 1253-1259, 2023 08 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37072323
11.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(7): 919-930, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35690073
12.
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
Gynecol Oncol
; 166(2): 254-262, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35718565
13.
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
Gynecol Oncol
; 167(3): 404-413, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36273926
14.
Data Set for the Reporting of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR).
Int J Gynecol Pathol
; 41(Suppl 1): S119-S142, 2022 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36305537
15.
British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic.
Int J Gynecol Cancer
; 32(1): 9-14, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34795019
16.
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study.
Int J Gynecol Cancer
; 32(6): 761-768, 2022 06 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35086926
17.
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(9): 1275-1289, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34363762
18.
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Lancet Oncol
; 22(2): 277-288, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33357510
19.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 22(5): 620-631, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33743851
20.
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Lancet Oncol
; 22(7): 1034-1046, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34143970